Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Assets (2016 - 2025)

Guided Therapeutics' Assets history spans 16 years, with the latest figure at $1.3 million for Q4 2025.

  • On a quarterly basis, Assets fell 3.92% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 3.92% decrease, with the full-year FY2025 number at $1.3 million, down 3.92% from a year prior.
  • Assets hit $1.3 million in Q4 2025 for Guided Therapeutics, up from $903000.0 in the prior quarter.
  • Over the last five years, Assets for GTHP hit a ceiling of $3.9 million in Q3 2022 and a floor of $903000.0 in Q3 2025.
  • Historically, Assets has averaged $1.9 million across 5 years, with a median of $1.7 million in 2021.
  • Biggest five-year swings in Assets: surged 548.9% in 2021 and later plummeted 51.51% in 2023.
  • Tracing GTHP's Assets over 5 years: stood at $2.0 million in 2021, then surged by 65.0% to $3.4 million in 2022, then tumbled by 50.42% to $1.7 million in 2023, then dropped by 17.44% to $1.4 million in 2024, then fell by 3.92% to $1.3 million in 2025.
  • Business Quant data shows Assets for GTHP at $1.3 million in Q4 2025, $903000.0 in Q3 2025, and $940000.0 in Q2 2025.